Oricare Pharma Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
- Paid Up Capital ₹ 0.50 M
- Company Age 6 Year, 10 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 5.20 M
- Revenue Growth -0.29%
- Profit Growth -517.74%
- Ebitda -41.27%
- Net Worth -23.50%
- Total Assets 11.03%
About Oricare Pharma
Oricare Pharma Private Limited (OPPL) is a Private Limited Indian Non-Government Company incorporated in India on 13 April 2018 (Six years and ten months 3 days old ). Its registered office is in Ahmedabad, Gujarat, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.50 M.
The company currently has active open charges totaling ₹5.20 M.
Pankaj Misra and Sumitra Devi serve as directors at the Company.
Company Details
-
Location
Ahmedabad, Gujarat, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
-
Website
-
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U74999GJ2018PTC101803
-
Company No.
101803
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
13 Apr 2018
-
Date of AGM
30 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Ahmedabad
Industry
Who are the key members and board of directors at Oricare Pharma?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Pankaj Misra
|
Director | 13-Apr-2018 | Current |
|
Sumitra Devi
|
Director | 13-Apr-2018 | Current |
Financial Performance of Oricare Pharma.
Oricare Pharma Private Limited, for the financial year ended 2023, experienced Minor drop in revenue, with a 0.29% decrease. The company also saw a substantial fall in profitability, with a 517.74% decrease in profit. The company's net worth observed a substantial decline by a decrease of 23.5%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Oricare Pharma?
Unlock access to Oricare Pharma's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
₹5.20 M
₹0
Charges Breakdown by Lending Institutions
- Others : 0.52 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 02 Jun 2020 | Others | ₹0.80 M | Open |
| 27 Apr 2020 | Others | ₹0.40 M | Open |
| 08 Aug 2019 | Others | ₹4.00 M | Open |
How Many Employees Work at Oricare Pharma?
Unlock and access historical data on people associated with Oricare Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Oricare Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Oricare Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.